Supernus Pharmaceuticals (SUPN) News Today $35.43 -0.34 (-0.95%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Wellington Management Group LLP Sells 14,350 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Wellington Management Group LLP lowered its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 35.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,326 shares of tDecember 20 at 3:39 AM | marketbeat.comKnight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in CanadaDecember 16, 2024 | globenewswire.comSupernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up - Should You Buy?December 15, 2024 | americanbankingnews.comSupernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up - Time to Buy?Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up - Here's What HappenedDecember 13, 2024 | marketbeat.comAshford Capital Management Inc. Has $16.96 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Ashford Capital Management Inc. lowered its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 23.6% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 544,035 shares of the specialty pharmaceutical company's stock after selliDecember 10, 2024 | marketbeat.comQuantbot Technologies LP Decreases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Quantbot Technologies LP cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 95.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,026 shares of the specialty pharmaceutical company's stock after selling 21,60December 8, 2024 | marketbeat.comSystematic Financial Management LP Buys New Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Systematic Financial Management LP purchased a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 28,185 shares of the specialty pharmaceDecember 7, 2024 | marketbeat.comPiper Sandler Sticks to Their Hold Rating for Supernus Pharmaceuticals (SUPN)December 6, 2024 | markets.businessinsider.comCharles Schwab Investment Management Inc. Purchases 91,354 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Charles Schwab Investment Management Inc. raised its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 14.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor ownDecember 6, 2024 | marketbeat.com37,110 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by PDT Partners LLCPDT Partners LLC acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 37,110 shares of the specialty pharmaceutical company's stock, valued at approximatelyDecember 2, 2024 | marketbeat.comSupernus to Participate in the 36th Annual Piper Sandler Healthcare ConferenceNovember 26, 2024 | globenewswire.comLoomis Sayles & Co. L P Reduces Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Loomis Sayles & Co. L P reduced its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,516,123 shares of the specialty pharmaceutical companyNovember 26, 2024 | marketbeat.comSegall Bryant & Hamill LLC Invests $791,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Segall Bryant & Hamill LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 25,377 shares of the specialty pharmaceutical companyNovember 25, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $6.70 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 145.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 214,864 shNovember 23, 2024 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Pacer Advisors Inc.Pacer Advisors Inc. grew its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 29.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,752,882 shares of the specialty phaNovember 22, 2024 | marketbeat.comMutual of America Capital Management LLC Sells 75,782 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Mutual of America Capital Management LLC reduced its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 27.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 202,654 shares of the specialty pharmaceutical companNovember 20, 2024 | marketbeat.comState of New Jersey Common Pension Fund D Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)State of New Jersey Common Pension Fund D purchased a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm purchased 56,885 shares of the specialty pharmaceutical company's stock, valued atNovember 19, 2024 | marketbeat.comPrincipal Financial Group Inc. Increases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Principal Financial Group Inc. raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 285,411 shares of the specialty pharmaceNovember 19, 2024 | marketbeat.com20,033 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Los Angeles Capital Management LLCLos Angeles Capital Management LLC purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,033 shares ofNovember 17, 2024 | marketbeat.comSupernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare ConferenceNovember 13, 2024 | globenewswire.comGSA Capital Partners LLP Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)GSA Capital Partners LLP boosted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 218.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,831 shares of the specialty phaNovember 13, 2024 | marketbeat.comSupernus Pharmaceuticals: Recently Launched Qelbree Is Powering GrowthNovember 12, 2024 | seekingalpha.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel Sells 14,213 SharesNovember 9, 2024 | insidertrades.comInsider Selling: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Sells 125,000 Shares of StockNovember 9, 2024 | insidertrades.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel Sells 14,213 SharesSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) Director Georges Gemayel sold 14,213 shares of the company's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the transaction, the director now directly owns 13,315 shares of the company's stock, valued at approximately $487,595.30. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.November 8, 2024 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack A. Khattar Sells 125,000 SharesSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) CEO Jack A. Khattar sold 125,000 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the transaction, the chief executive officer now directly owns 926,172 shares of the company's stock, valued at $33,971,988.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.November 8, 2024 | marketbeat.comSupernus Pharmaceuticals Third Quarter 2024 Earnings: Beats ExpectationsNovember 6, 2024 | finance.yahoo.comStifel Nicolaus Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)November 6, 2024 | markets.businessinsider.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | msn.comSupernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...November 5, 2024 | finance.yahoo.comSupernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year High Following Earnings BeatSupernus Pharmaceuticals (NASDAQ:SUPN) Hits New 1-Year High After Earnings BeatNovember 5, 2024 | marketbeat.comSupernus Pharmaceuticals Reports Strong Q3 2024 ResultsNovember 5, 2024 | markets.businessinsider.comSupernus jumps 3% to $35.77 after Q3 beat, guidance raiseNovember 5, 2024 | markets.businessinsider.comStrong Q3 Performance and Promising Future for Supernus Pharmaceuticals Backed by Qelbree’s SuccessNovember 5, 2024 | markets.businessinsider.comSupernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | seekingalpha.comSupernus Announces Third Quarter 2024 Financial ResultsNovember 4, 2024 | markets.businessinsider.comSupernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings ResultsSupernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) posted its quarterly earnings data on Monday. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.25. The business had revenue of $175.70 million during the quarter, compared to analysts' expectations of $157.35 million. Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. The business's revenue was up 14.2% on a year-over-year basis. During the same period last year, the firm posted ($0.29) earnings per share.November 4, 2024 | marketbeat.comStephens Investment Management Group LLC Boosts Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Stephens Investment Management Group LLC increased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 1.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional invesNovember 1, 2024 | marketbeat.comSupernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024October 31, 2024 | globenewswire.comSupernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on MondaySupernus Pharmaceuticals (NASDAQ:SUPN) will be releasing earnings after the market closes on Monday, November 4, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638117)October 28, 2024 | marketbeat.comSupernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial ResultsOctober 21, 2024 | globenewswire.comSupernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 12-Month High - Time to Buy?Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month High - Here's What HappenedOctober 21, 2024 | marketbeat.comStifel Nicolaus Reaffirms Their Hold Rating on Supernus Pharmaceuticals (SUPN)October 19, 2024 | markets.businessinsider.comSupernus Pharmaceuticals (SUPN) Gets a Buy from TD CowenOctober 19, 2024 | markets.businessinsider.comExchange Traded Concepts LLC Invests $672,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Exchange Traded Concepts LLC acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 21,559 shares of the specialty pharmaceutical companyOctober 19, 2024 | marketbeat.comSupernus Pharmaceuticals, Inc.: Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive DisorderOctober 18, 2024 | finanznachrichten.deSupernus Announces Promising Data From Phase 2a Study Of SPN-820 In Major Depressive DisorderOctober 18, 2024 | markets.businessinsider.comSupernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive DisorderOctober 17, 2024 | globenewswire.comMillennium Management LLC Acquires 128,743 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Millennium Management LLC increased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 395.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 161,332 shares of thOctober 13, 2024 | marketbeat.comSupernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive DisorderOctober 10, 2024 | globenewswire.com Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode. >> Register for the Workshop Now SUPN Media Mentions By Week SUPN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SUPN News Sentiment▼0.720.60▲Average Medical News Sentiment SUPN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SUPN Articles This Week▼33▲SUPN Articles Average Week Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies JAZZ News CORT News PRGO News PCRX News OMER News NKTR News ASMB News CPIX News LLY News JNJ News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SUPN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
